US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
美国政府提供7500万美元支持用于新冠肺炎疫苗的Lipid Systems扩展
- The U.S. government will provide up to $75 million to expand U.K.-listed Croda International Plc's (OTC:COIHF) U.S. manufacturing capacity of ingredients for lipid systems used in novel therapeutic drugs, such as mRNA vaccines.
- Croda will also invest up to $58 million.
- The investment will be used to establish a new lipid facility in Lamar, Pennsylvania. Construction is expected to start later this year, with the new capacity anticipated in 2025.
- The investment supports the expansion of Croda's portfolio, by creating a third manufacturing site for lipid systems, alongside Croda's existing Alabaster, Alabama, U.S. (Avanti) and Leek, U.K. capabilities.
- The cooperative agreement is a joint award from the Biomedical Advanced Research and Development Authority (BARDA), and an arm of the U.S. Department of defense will join forces for preparedness for future health emergencies.
- Financial Times writes that Pfizer Inc (NYSE:PFE) / BioNTech SE (NASDAQ:BNTX) and Moderna Inc's (NASDAQ:MRNA) COVID-19 vaccines were the first approved jabs to be made with mRNA technology.
- The vaccines rely on bubbles of fat known as lipid nanoparticles to deliver genetic codes that teach the immune system to recognize the virus.
- Lipid systems offer significant potential as the delivery system for many nucleic acid applications, including novel mRNA-based therapeutics, such as flu vaccines and cancer treatments.
- Given the current clinical development pipeline's scale, the lipid systems market is expected to grow significantly over the next ten years.
- Image by Spencer Davis from Pixabay
- 美国政府将提供至多7500万美元扩大在英国上市的规模克罗达国际公司(场外交易代码：COIHF)用于新型治疗药物(如信使核糖核酸疫苗)的脂质系统成分的美国制造能力。
- 克罗达还将投资高达5800万美元。
- 这笔投资将用于在宾夕法尼亚州拉马尔建立一个新的脂质设施。建设预计将于今年晚些时候开始，新的产能预计在2025年。
- 这笔投资通过创建第三个脂质系统制造基地，支持克罗达扩大产品组合，与克罗达现有的阿拉巴马州阿拉巴斯市(Avanti)和英国Leek工厂并驾齐驱。
- 这项合作协议是由生物医学高级研究和发展局(BARDA)联合颁发的，美国国防部的一个部门将联合起来，为未来的卫生紧急情况做好准备。
- 英国《金融时报》写道辉瑞(纽约证券交易所市场代码：PFE)/BioNTech SE(纳斯达克：bntx)和Moderna(纳斯达克：信使核糖核酸)新冠肺炎疫苗是第一批被批准使用信使核糖核酸技术制造的疫苗。
- 这些疫苗依靠被称为脂质纳米颗粒的脂肪气泡来传递遗传密码，教会免疫系统识别病毒。
- 脂质系统为许多核酸应用提供了巨大的潜力，包括基于信使核糖核酸的新疗法，如流感疫苗和癌症治疗。
- 鉴于目前临床开发管道的规模，脂质系统市场预计在未来十年内将显著增长。
- 来自Pixabay的斯宾塞·戴维斯摄